Industry Spotlight Session 51

30 Mar 2026 3:15 p.m. 3:45 p.m.
Spotlight Stage 2
RajivAgarwal Chair United States

Session Title : Guided by evidence: a unified approach to CKD, diabetes and HF management

Organized By : Bayer AG

Session Description : This spotlight session will explore the importance of targeting albuminuria as a modifiable CKD and cardiovascular risk factor and examine finerenone’s role as a foundational therapy within a multi-pillar CKM approach. A case-based panel discussion will address real-world barriers to delivering comprehensive cardiorenal care and provide practical insights to help clinicians integrate these principles into multidisciplinary practice.

Learning Objectives :

1. Understand the rationale for a pillar-based approach to CKD, diabetes and HF management and the evidence base supporting this approach
2. Identify current gaps and challenges in implementing multimodal therapy and explore practical strategies to overcome these barriers
Time Session
3:15 p.m.
3:25 p.m.
The Pillar Perspective: A Deep Dive Into Clinical Evidence
RajivAgarwal Speaker ragarwal@iu.eduUnited States
3:25 p.m.
3:45 p.m.
Panel Discussion
Multimodal Management of CKD and HF
RajivAgarwal Moderator ragarwal@iu.eduUnited States
Jozine TerMaaten Panel j.m.ter.maaten@umcg.nlNetherlands
NaokiSato Panel nms-ns@nms.ac.jpJapan